Confo Therapeutics and DyNAbind Announce Drug Discovery Collaboration to Identify Novel GPCR-Modulating Compounds

Confo Therapeutics and DyNAbind announce a drug discovery collaboration on an undisclosed G-protein coupled receptor (GPCR). The collaboration will combine ConfoBody-enabled GPCRs with DyNAbind’s Dynamic DNA-encoded Library for the discovery of small molecule GPCR-modulating compounds.